Topics

Mutational intensity influences a tumour's response to PD-1 immunotherapy

06:35 EDT 3 May 2019 | ecancermedicalscience

Following FDA approval last year of PD-1 immune checkpoint inhibitors for tumours with mismatch repair deficiency, a new study reveals more about why responses of these tumours to this immunotherapy vary, specifically implicating mutation intensity. The...

Original Article: Mutational intensity influences a tumour's response to PD-1 immunotherapy

NEXT ARTICLE

More From BioPortfolio on "Mutational intensity influences a tumour's response to PD-1 immunotherapy"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...